Response Biomedical expands distribution of cardiovascular products in the U.S.

Vancouver's Response Biomedical Corp. (TSC: RBM) (OTCBB: RPBIF) has entered into a distribution agreement with Laboratory Supply Company, Inc. (LABSCO) in Louisville, Kentucky, to distribute ...

Vancouver's Response Biomedical Corp. (TSC: RBM) (OTCBB: RPBIF) has entered into a distribution agreement with Laboratory Supply Company, Inc. (LABSCO) in Louisville, Kentucky, to distribute cardiovascular products in the U.S. to hospitals with fewer than 150 beds.

LABSCO is the largest privately held distributor of clinical lab products in the U.S.

"This is a very important agreement for Response as it marks a significant step into the U.S. market for POCT [point-of-care testing] in the cardiovascular areana, which is one of the largest markets in the world," said Tim Shannon, Response Biomedical Corp.'s senior vice-president of worldwide sales and marketing.

"LABSCO has the experience and reputation to maximize our efforts to gain traction and to help us penetrate a market that we believe will greatly enhance our growth in the near term and beyond."

The POCT market in the U.S. is worth an estimated $3.1 billion.

ecrawford@biv.com

@EmmaCrawfordBIV

comments powered by Disqus

More from Technology

Vancouver's cash-strapped startups urged to consider costly legal mistakes

Read Article

Cascadian connections hit transportation roadblocks despite innovators' enthusiasm

Lack of efficient transportation links hamper further Vancouver-Seattle integration  

Read Article

Syngas conference to be held in Vancouver for first time

American conference drawn to Vancouver by cheaper hotel prices, direct flights to Asia

Read Article

Microsoft’s Bill Gates, Satya Nadella champion Vancouver’s potential as innovation hub

Ask the CEO of Microsoft about the innovations coming out of Vancouver and...

Read Article

Subscribe to our mailing lists

* indicates required

Newsletters

* You can modify your newsletter subscriptions at the bottom of any newsletter you receive.
×